PCN177 Assessment of Reimbursement Processes and Outcomes for Cancer Drugs in Croatia – Comparison to NICE and NCCN Guidelines

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1276
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

NCCN Guidelines Updates: Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2017English

NCCN Guidelines and the International Community

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

Time to Reimbursement for Oncology Drugs in EU5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

An Examination of the Regulatory and Reimbursement Processes for Biobetters and Comparison With Biosimilars

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

New NCCN Guidelines: Cancer Management in People Living With HIV

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Pcn230 - Are Nice and the SMC Diverging in Their Assessment of Oncology Drugs?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy